Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB414 in mild to moderate plaque psoriasis
NCT03445013Phase 1Completed
- Sponsor
- Novan
- Start
- Oct 2017
- Primary completion
- Jan 2018
- Modality
- Polymer-based Nanoparticles, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in plaque psoriasis comparing SB414 6% with Vehicle Cream (2 arms). Primary endpoint: Plasma concentrations of hMAP3 at Day 29. Started Oct 2017; status: completed.
02
Drugs
berdazimer
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03445013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03445013.